World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
24301
World Ranking
2108
National Ranking
53

Alexandra Trkola publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Alexandra Trkola sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 328 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Alexandra Trkola D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Alexandra Trkola sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Alexandra Trkola is affiliated with the University of Zurich in Switzerland. Their research spans multiple fields within medicine, particularly focusing on infectious diseases, virology, epidemiology, emergency medicine, and immunology.

The main topics of their work include the study and treatment of viral infections such as HIV and SARS-CoV-2. Key areas of focus are:

  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV-related health complications and treatments
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing

Frequently collaborating with other researchers, Alexandra Trkola has worked extensively with colleagues including:

  • Huldrych F. Günthard
  • Roger D. Kouyos
  • Enos Bernasconi
  • Matthias Cavassini
  • Dominique L. Braun

Their research outputs have been published in a variety of journals. The most frequent publication venues are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Infectious Diseases
  • The Journal of Infectious Diseases
  • Open Forum Infectious Diseases
  • Journal of Antimicrobial Chemotherapy

Some notable recent papers authored by or associated with Alexandra Trkola include:

  • "Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2" (2020, mBio)
  • "Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)" (2021, International Journal of Epidemiology)
  • "Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools" (2021, BMJ)
  • "A highly virulent variant of HIV-1 circulating in the Netherlands" (2022, Science)
  • "SARS-CoV-2 variants reveal features critical for replication in primary human cells" (2021, PLoS Biology)

Best Publications

  • CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

    Alexandra Trkola;Tatjana Dragic;James Arthos;James M. Binley

  • Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

    A Trkola;M Purtscher;T Muster;C Ballaun

  • A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

    T Muster;F Steindl;M Purtscher;A Trkola

  • Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

    A. Buchacher;R. Predl;K. Strutzenberger;W. Steinfellner

  • Co-receptors for HIV-1 entry.

    John P Moore;Alexandra Trkola;Tatjana Dragic

  • Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

    Alexandra Trkola;Herbert Kuster;Peter Rusert;Beda Joos

  • Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

    A Trkola;A B Pomales;H Yuan;B Korber

  • A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

    Tatjana Dragic;Alexandra Trkola;Daniah A. D. Thompson;Emmanuel G. Cormier

  • SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

    Julie M. Strizki;Serena Xu;Nicole E. Wagner;Lisa Wojcik

  • A Broadly Neutralizing Human Monoclonal Antibody against gp41 of Human Immunodeficiency Virus Type 1

    Martin Purtscher;Alexandra Trkola;Gerhard Gruber;Andrea Buchacher

  • HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

    Alexandra Trkola;Shawn E. Kuhmann;Julie M. Strizki;Elizabeth Maxwell

  • Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS

    T Muster;R Guinea;A Trkola;M Purtscher

  • Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

    T R Fouts;J M Binley;A Trkola;J E Robinson

  • HIV rebounds from latently infected cells, rather than from continuing low-level replication.

    Beda Joos;Marek Fischer;Herbert Kuster;Satish K. Pillai

  • Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

    Alexandra Trkola;Thomas J. Ketas;Kirsten A. Nagashima;Lu Zhao

  • Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry

    Tatjana Dragic;Alexandra Trkola;Steven W. Lin;Kirsten A. Nagashima

  • The BBXB Motif of RANTES Is the Principal Site for Heparin Binding and Controls Receptor Selectivity

    Amanda E.I. Proudfoot;Sarah Fritchley;Frédéric Borlat;Jeffrey P. Shaw

  • Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

    Fotini Tsamis;Svetlana Gavrilov;Francis Kajumo;Christoph Seibert

  • Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines

    R. I. Connor;B. T. M. Korber;B. S. Graham;B. H. Hahn

  • HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

    Gabriel M. Ortiz;Douglas F. Nixon;Alexandra Trkola;James Binley

Frequent Co-Authors

Huldrych F. Günthard
Huldrych F. Günthard University of Zurich
Michael Huber
Michael Huber University of Zurich
John P. Moore
John P. Moore Cornell University
Jürg Böni
Jürg Böni University of Zurich
Hermann Katinger
Hermann Katinger BOKU University
Rainer Weber
Rainer Weber University of Zurich
Marek Fischer
Marek Fischer University of Zurich
Roger D. Kouyos
Roger D. Kouyos University of Zurich
Karin J. Metzner
Karin J. Metzner University of Zurich
Stefan Schmutz
Stefan Schmutz BOKU University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those pursuing a career in Immunology in the USA, expanding your qualifications through related nursing degrees can open diverse opportunities. Many students transition from foundational nursing roles to more specialized ones, such as moving from Family Nurse Practitioner (FNP) roles to advanced clinical positions. Programs like the fnp to acute care np bridge program help facilitate this critical career shift efficiently.

If you’re an RN looking to advance quickly, exploring accelerated rn to np programs offers an expedited pathway to becoming a nurse practitioner. These programs blend rigorous coursework with clinical experience tailored to enhance your practice in immunology-related fields.

For those entering nursing from non-nursing backgrounds, online absn programs for non nurses provide accessible routes to build foundational knowledge and skills while balancing other commitments. Likewise, choosing among the easiest absn program to get into can make your transition smoother and more manageable.

Whether you are deepening your expertise or changing your professional trajectory, these pathways offer flexibility and growth essential for success in Immunology and healthcare careers.

Best Scientists Citing Alexandra Trkola

Trending Scientists

Recently Published Articles